PILOT-STUDY FOR PROFILING PSA GLYCOSYLATION AS PUTATIVE PROSTATE CANCER BIOMARKER BY HIGH RESOLUTION NATIVE MASS SPECTROMETRY

PILOT-STUDY FOR PROFILING PSA GLYCOSYLATION AS PUTATIVE PROSTATE CANCER BIOMARKER BY HIGH RESOLUTION NATIVE MASS SPECTROMETRY - Profiling PSA glycosylation

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON42143

Enrollment

Registered

2015-04-01

Start date

2015-07-21

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Interventions

Biomarker

Glycosylation

Prostate

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria for patients: -Male gender -Signed written informed consent -Biopsy-proven prostate cancer, eligible for surgery -Age 55 - 70 years -Willing and able to collect semen;Inclusion criteria for controls: -Male gender -Visiting the outpatient clinic because of lower urinary tract symptoms (LUTS) -Signed written informed consent -Serum PSA

Exclusion criteria

Exclusion criteria: -Urinary tract infection

Design outcomes

Primary

Measure	Time frame
- PSA-glycosylation patterns (finger-prints) for prostate cancer versus normal controls - Correlation between PSA-glycosylation patterns and Gleason grade/tumour stage (clinical and pathological)	—

Secondary

Measure	Time frame
Correlation between PSA-glycosylation patterns and PSA-level in serum	—

Countries

The Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)